Congress mandates insurance coverage for ovarian cancer genetic testing and preventive surgery
S. 5554 — Ovarian Cancer IMPACT Act · Filed by Elissa Slotkin (D-MI) · 1 cosponsor · Introduced Sep 24, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill expands federal programs to improve ovarian cancer prevention, detection, and treatment by funding public awareness campaigns, demonstration projects in underserved areas, and requiring health insurance plans to cover genetic counseling, genetic testing, and risk-reducing surgeries for people at hereditary risk. It directs the Department of Health and Human Services to coordinate efforts across agencies and report on progress in closing care gaps, particularly in rural and low-income communities.
Why we flagged it
The bill's operative mechanism is straightforward: it funds awareness and demonstration projects, mandates insurance coverage for genetic testing and preventive interventions, and directs federal agencies to coordinate and report on implementation. No hidden mechanisms, no narrow carve-outs, no self-dealing provisions.
What the text implies
- Insurance coverage mandate may increase demand for genetic counseling and testing services, potentially straining capacity in underserved areas unless demonstration projects successfully build provider infrastructure.
- Requirement that 'least restrictive' guideline applies when professional organizations conflict may expand coverage scope beyond some insurers' initial interpretation, increasing plan costs.
- Tumor genomic profiling and somatic mutation testing coverage (subsection (a)(1)(B)(iv)) extends beyond germline hereditary risk assessment to post-diagnosis treatment selection, broadening the bill's scope beyond prevention.
- Privacy protections language (subsection (g)) references 'all applicable Federal and State privacy laws' but does not establish new genetic privacy safeguards specific to ovarian cancer testing, leaving implementation to existing frameworks.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Ordinary people at hereditary ovarian cancer risk gain access to genetic counseling, testing, and preventive surgeries that may reduce cancer incidence and mortality. Rural and medically underserved populations, who face documented disparities in access to specialty care, are explicitly targeted for outreach and demonstration projects. Insurance coverage mandates remove cost barriers to evidence-based preventive interventions.
Who stands to gain
- genetic testing laboratories and companies offering multi-gene panel testing
- genetic counseling providers and telehealth platforms offering remote counseling
- academic medical centers and specialty oncology practices receiving demonstration project grants
- rural hospitals and community health centers receiving rural outreach funding
Named in the bill
Department of Health and Human Services, Centers for Disease Control and Prevention, Health Resources and Services Administration, National Cancer Institute, National Comprehensive Cancer Network, American Society of Clinical Oncology, Society of Gynecologic Oncology, State, local, and Tribal public health departments, Community health centers, Rural hospitals, Academic medical centers, Nonprofit organizations
Where it stands
1 cosponsor: 1 Republicans.
- Sep 24, 2026 — Introduced · Congress.gov: “Introduced in Senate”
- Sep 24, 2026 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Sep 2026 to Sep 2026. Those filings disclosed $250,000 in lobbying spend. A filing names 37 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
Elissa Slotkin, the sponsor, reported $45,050 in PAC receipts in the 2026 cycle.
- American College of Obstetricians and Gynecologists — $250,000 on 1 filing
Lobbying Disclosure Act filings through Oct 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (12,938 characters) on Oct 7, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 17,684 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Sep 2026 to Sep 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Oct 20, 2026 · page rendered 2026-11-16.
“Congress mandates insurance coverage for ovarian cancer genetic testing and preventive surgery” QuorumCivic. https://share.quorumcivic.app/bill/119/s5554 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.